Jam

Zeus North America Mining Corp. announced promising rock grab sample results from its Selway Property in Idaho. The property, located east of Kamiah, Idaho, targets an intrusive-related Au-Ag vein deposit. Historical samples yielded significant silver and gold. Zeus plans follow-up sampling and ground geophysical programs in 2025. Dean Besserer, President & CEO, a Qualified Person, reviewed and approved the informational release.

TotalEnergies acquired a 25% stake in 40 offshore exploration leases from Chevron in the U.S., spanning ~1,000 sq km across Walker Ridge, Mississippi Canyon, and East Breaks areas. This expands TotalEnergies’ U.S. offshore presence, building on collaborations with Chevron in projects like Ballymore and Anchor. The move reinforces TotalEnergies’ commitment to low-emission projects and its integrated energy strategy, including significant investments in LNG and renewables in the U.S. since 2022.

e.l.f. Cosmetics introduces “color e.l.f.nalysis,” a free digital tool offering personalized beauty advice. By analyzing a selfie, the tool determines a user’s color season and recommends curated Pinterest boards featuring shoppable e.l.f. products. Developed in partnership with Pinterest, the tool aims to democratize color analysis and make personalized beauty accessible.

Mariah Carey will soon own an FF 91 2.0 and showcases the vehicle and FFZERO1 concept car in her new music video, “Type Dangerous,” which also features MrBeast. This partnership aims to reinforce Faraday Future’s “Ultimate AI TechLuxury” branding. YT Jia, Faraday Future’s founder, welcomes Carey to the FF 91 2.0 owner family.

Innovent Biologics initiated a Phase 3 trial (GLORY-OSA) in China for mazdutide, a dual GCG and GLP-1 receptor agonist. The study will evaluate the drug’s efficacy and safety in Chinese patients with obesity and moderate-to-severe obstructive sleep apnea (OSA). Mazdutide has shown potential in weight loss and metabolic improvements, representing a potential treatment for a condition that affects millions in China, where current diagnosis rates are low. This marks the seventh Phase 3 study for the drug.

Bombardier’s Global 7500 sets a new speed record on a flight from Montreal to Paris, completing the journey in 5 hours and 30 minutes at over 1,000 km/hr. The aircraft showcases its superior performance and ability to connect global cities swiftly. The Global 7500 consistently achieves impressive real-world results, solidifying its place as a premier business jet, with the Global 8000 on the horizon.

The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.

FranklinCovey is hosting a webinar on June 16, 2025, featuring Amy Edmondson, Stephen M. R. Covey, and Liz Wiseman. The discussion will delve into how leaders can thrive amidst constant disruption, addressing the leadership crisis, engagement recession, and adaptability dilemma. The event will explore strategies for navigating uncertainty and fostering successful, resilient organizations.

Upstream Bio announced promising data on verekitug, a lead candidate targeting the TSLP receptor, presented at the EAACI Congress. Modeling data suggests enhanced potency compared to tezepelumab, potentially offering a differentiated profile across inflammatory diseases like asthma, COPD, and CRSwNP. Phase 2 trials for CRSwNP are expected in Q3 2025, followed by severe asthma data in 2026’s first half.

Phase 1b/2 trial data showed that epcoritamab combined with R-ICE achieved an 87% overall response rate and a 65% complete response rate in relapsed/refractory DLBCL patients, with 65% proceeding to ASCT. These results, presented at EHA, suggest epcoritamab may improve ASCT eligibility and represent a potential new treatment option.